Does genotyping of risk-associated single nucleotide polymorphisms improve patient selection for prostate biopsy when combined with a prostate cancer risk calculator?

Prostate

Volumn 74, Issue 4, 2014, Pages 365-371

  Butoescu, Valentina ^a   Ambroise, Jérôme ^b   Stainier, Annabelle ^a   Dekairelle, Anne France ^b   Gala, Jean Luc ^b,c   Tombal, Bertrand ^a  

^a CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^b UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^c Defense Laboratories Department   (Belgium)

Author keywords

Genetic; Prostate biopsy; Prostate cancer; Risk calculator; Single nucleotidepolymorphisms

Indexed keywords

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BOOTSTRAPPING; CANCER RISK; COMPARATIVE STUDY; CONFIDENCE INTERVAL; CONTROLLED STUDY; GENETIC ASSOCIATION; GENETIC MODEL; GENETIC RISK; GENOTYPE; HUMAN; HUMAN TISSUE; INTEGRATED DISCRIMINATION IMPROVEMENT; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NET RECLASSIFICATION IMPROVEMENT; PATIENT SELECTION; PREDICTION; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATE CANCER RISK CALCULATOR; RECEIVER OPERATING CHARACTERISTIC; RISK ASSESSMENT; SCORING SYSTEM; SINGLE NUCLEOTIDE POLYMORPHISM; VERY ELDERLY;

GENETIC; PROSTATE BIOPSY; PROSTATE-CANCER; RISK-CALCULATOR; SINGLE-NUCLEOTIDE-POLYMORPHISMS;

BIOPSY; DIGITAL RECTAL EXAMINATION; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; PATIENT SELECTION; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSTATE; PROSTATIC NEOPLASMS; RISK;

EID: 84895930998     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.22757     Document Type: Article

References (29)

1. Heidenreich A, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V, Mottet N, Schmid HP, Van Der Kwast T, Wiegel T, Zattoni F. EAU guidelines on prostate cancer. Part 1: Screening, diagnosis, and treatment of clinically localised disease. Eur Urol 2011;59(1):61-71.
2. Kranse R, Roobol M, Schroder FH. A graphical device to represent the outcomes of a logistic regression analysis. Prostate 2008;68(15):1674-1680.
3. Van Vugt HA, Kranse R, Steyerberg EW, Van Der Poel HG, Busstra M, Kil P, Oomens EH, De Jong IJ, Bangma CH, Roobol MJ. Prospective validation of a risk calculator which calculates the probability of a positive prostate biopsy in a contemporary clinical cohort. Eur J Cancer 2012;48(12):1809-1815.
4. Ankerst DP, Boeck A, Freedland SJ, Stephen Jones J, Cronin AM, Roobol MJ, Hugosson J, Kattan MW, Klein EA, Hamdy F, Neal D, Donovan J, Parekh DJ, Klocker H, Horninger W, Benchikh A, Salama G, Villers A, Moreira DM, Schroder FH, Lilja H, Vickers AJ, Thompson IM. Evaluating the Prostate Cancer Prevention Trial High Grade prostate cancer risk calculator in 10 international biopsy cohorts: Results from the prostate biopsy collaborative group. World J Urol. 2012 Apr. 22. [Epub ahead of print]. doi: 10.1007/s00345-012-0869-2
5. Amundadottir LT, Sulem P, Gudmundsson J, Helgason A, Baker A, Agnarsson BA, Sigurdsson A, Benediktsdottir KR, Cazier JB, Sainz J, Jakobsdottir M, Kostic J, Magnusdottir DN, Ghosh S, Agnarsson K, Birgisdottir B, Le Roux L, Olafsdottir A, Blondal T, Andresdottir M, Gretarsdottir OS, Bergthorsson JT, Gudbjartsson D, Gylfason A, Thorleifsson G, Manolescu A, Kristjansson K, Geirsson G, Isaksson H, Douglas J, Johansson JE, Balter K, Wiklund F, Montie JE, Yu X, Suarez BK, Ober C, Cooney KA, Gronberg H, Catalona WJ, Einarsson GV, Barkardottir RB, Gulcher JR, Kong A, Thorsteinsdottir U, Stefansson K. A common variant associated with prostate cancer in European and African populations. Nat Genet 2006;38(6):652-658.
6. Kote-Jarai Z, Easton DF, Stanford JL, Ostrander EA, Schleutker J, Ingles SA, Schaid D, Thibodeau S, Dork T, Neal D, Donovan J, Hamdy F, Cox A, Maier C, Vogel W, Guy M, Muir K, Lophatananon A, Kedda MA, Spurdle A, Steginga S, John EM, Giles G, Hopper J, Chappuis PO, Hutter P, Foulkes WD, Hamel N, Salinas CA, Koopmeiners JS, Karyadi DM, Johanneson B, Wahlfors T, Tammela TL, Stern MC, Corral R, McDonnell SK, Schurmann P, Meyer A, Kuefer R, Leongamornlert DA, Tymrakiewicz M, Liu JF, O'Mara T, Gardiner RA, Aitken J, Joshi AD, Severi G, English DR, Southey M, Edwards SM, Al Olama AA, Eeles RA. Multiple Novel Prostate Cancer Predisposition Loci Confirmed by an International Study: The PRACTICAL Consortium. Cancer Epidemiol Biomar Prevent 2008;17(8):2052-2061.
7. Eeles RA, Kote-Jarai Z, Giles GG, Olama AAA, Guy M, Jugurnauth SK, Mulholland S, Leongamornlert DA, Edwards SM, Morrison J, Field HI, Southey MC, Severi G, Donovan JL, Hamdy FC, Dearnaley DP, Muir KR, Smith C, Bagnato M, Ardern-Jones AT, Hall AL, O'Brien LT, Gehr-Swain BN, Wilkinson RA, Cox A, Lewis S, Brown PM, Jhavar SG, Tymrakiewicz M, Lophatananon A, Bryant SL, Horwich A, Huddart RA, Khoo VS, Parker CC, Woodhouse CJ, Thompson A, Christmas T, Ogden C, Fisher C, Jamieson C, Cooper CS, English DR, Hopper JL, Neal DE, Easton DF. Multiple newly identified loci associated with prostate cancer susceptibility. Nat Genet 2008;40(3):316-321.
8. Freedman ML, Haiman CA, Patterson N, McDonald GJ, Tandon A, Waliszewska A, Penney K, Steen RG, Ardlie K, John EM, Oakley-Girvan I, Whittemore AS, Cooney KA, Ingles SA, Altshuler D, Henderson BE, Reich D. Admixture mapping identifies 8q24 as a prostate cancer risk locus in African-American men. Proc Natl Acad Sci U S A 2006;103(38):14068-14073.
9. Gudmundsson J, Sulem P, Manolescu A, Amundadottir LT, Gudbjartsson D, Helgason A, Rafnar T, Bergthorsson JT, Agnarsson BA, Baker A, Sigurdsson A, Benediktsdottir KR, Jakobsdottir M, Xu J, Blondal T, Kostic J, Sun J, Ghosh S, Stacey SN, Mouy M, Saemundsdottir J, Backman VM, Kristjansson K, Tres A, Partin AW, Albers-Akkers MT, Godino-Ivan Marcos J, Walsh PC, Swinkels DW, Navarrete S, Isaacs SD, Aben KK, Graif T, Cashy J, Ruiz-Echarri M, Wiley KE, Suarez BK, Witjes JA, Frigge M, Ober C, Jonsson E, Einarsson GV, Mayordomo JI, Kiemeney LA, Isaacs WB, Catalona WJ, Barkardottir RB, Gulcher JR, Thorsteinsdottir U, Kong A, Stefansson K. Genome-wide association study identifies a second prostate cancer susceptibility variant at 8q24. Nat Genet 2007;39(5):631-637.
10. Gudmundsson J, Sulem P, Steinthorsdottir V, Bergthorsson JT, Thorleifsson G, Manolescu A, Rafnar T, Gudbjartsson D, Agnarsson BA, Baker A, Sigurdsson A, Benediktsdottir KR, Jakobsdottir M, Blondal T, Stacey SN, Helgason A, Gunnarsdottir S, Olafsdottir A, Kristinsson KT, Birgisdottir B, Ghosh S, Thorlacius S, Magnusdottir D, Stefansdottir G, Kristjansson K, Bagger Y, Wilensky RL, Reilly MP, Morris AD, Kimber CH, Adeyemo A, Chen Y, Zhou J, So WY, Tong PC, Ng MC, Hansen T, Andersen G, Borch-Johnsen K, Jorgensen T, Tres A, Fuertes F, Ruiz-Echarri M, Asin L, Saez B, Van Boven E, Klaver S, Swinkels DW, Aben KK, Graif T, Cashy J, Suarez BK, Van VierssenTrip O, Frigge ML, Ober C, Hofker MH, Wijmenga C, Christiansen C, Rader DJ, Palmer CN, Rotimi C, Chan JC, Pedersen O, Sigurdsson G, Benediktsson R, Jonsson E, Einarsson GV, Mayordomo JI, Catalona WJ, Kiemeney LA, Barkardottir RB, Gulcher JR, Thorsteinsdottir U, Kong A, Stefansson K. Two variants on chromosome 17 confer prostate cancer risk, and the one in TCF2 protects against type 2 diabetes. Nat Genet 2007;39(8):977-983.
11. Thomas G, Jacobs KB, Yeager M, Kraft P, Wacholder S, Orr N, Yu K, Chatterjee N, Welch R, Hutchinson A, Crenshaw A, Cancel-Tassin G, Staats BJ, Wang Z, Gonzalez-Bosquet J, Fang J, Deng X, Berndt SI, Calle EE, Feigelson HS, Thun MJ, Rodriguez C, Albanes D, Virtamo J, Weinstein S, Schumacher FR, Giovannucci E, Willett WC, Cussenot O, Valeri A, Andriole GL, Crawford ED, Tucker M, Gerhard DS, Fraumeni JF Jr, Hoover R, Hayes RB, Hunter DJ, Chanock SJ. Multiple loci identified in a genomewide association study of prostate cancer. Nat Genet 2008;40(3):310-315.
12. Yeager M, Orr N, Hayes RB, Jacobs KB, Kraft P, Wacholder S, Minichiello MJ, Fearnhead P, Yu K, Chatterjee N, Wang Z, Welch R, Staats BJ, Calle EE, Feigelson HS, Thun MJ, Rodriguez C, Albanes D, Virtamo J, Weinstein S, Schumacher FR, Giovannucci E, Willett WC, Cancel-Tassin G, Cussenot O, Valeri A, Andriole GL, Gelmann EP, Tucker M, Gerhard DS, Fraumeni JF Jr, Hoover R, Hunter DJ, Chanock SJ, Thomas G. Genome-wide association study of prostate cancer identifies a second risk locus at 8q24. Nat Genet 2007;39(5):645-649.
13. Witte JS. Multiple prostate cancer risk variants on 8q24. Nat Genet 2007;39(5):579-580.
14. Beebe-Dimmer JL, Levin AM, Ray AM, Zuhlke KA, Machiela MJ, Halstead-Nussloch BA, Johnson GR, Cooney KA, Douglas JA. Chromosome 8q24 markers: Risk of early-onset and familial prostate cancer. Int J Cancer 2008;122(12):2876-2879.
15. Camp NJ, Farnham JM, Wong J, Christensen GB, Thomas A, Cannon-Albright LA. Replication of the 10q11 and Xp11 Prostate cancer risk variants: Results from a Utah pedigree-based study. Cancer Epidemiol Biomar Prevent 2009;18(4):1290-1294.
16. Ross RW, Oh WK, Xie W, Pomerantz M, Nakabayashi M, Sartor O, Taplin ME, Regan MM, Kantoff PW, Freedman M. Inherited variation in the androgen pathway is associated with the efficacy of androgen-deprivation therapy in men with prostate cancer. J Clin Oncol 2008;26(6):842-847.
17. Zheng SL, Sun J, Wiklund F, Smith S, Stattin PR, Li G, Adami H-O, Hsu F-C, Zhu Y, Bälter K, Kader AK, Turner AR, Liu W, Bleecker ER, Meyers DA, Duggan D, Carpten JD, Chang B-L, Isaacs WB, Xu J, Grönberg H. Cumulative association of five genetic variants with prostate cancer. N Engl J Med 2008;358(9):910-919.
18. Lindstrom S, Schumacher F, Siddiq A, Travis RC, Campa D, Berndt SI, Diver WR, Severi G, Allen N, Andriole G, Bueno-de-Mesquita B, Chanock SJ, Crawford D, Gaziano JM, Giles GG, Giovannucci E, Guo C, Haiman CA, Hayes RB, Halkjaer J, Hunter DJ, Johansson M, Kaaks R, Kolonel LN, Navarro C, Riboli E, Sacerdote C, Stampfer M, Stram DO, Thun MJ, Trichopoulos D, Virtamo J, Weinstein SJ, Yeager M, Henderson B, Ma J, Le Marchand L, Albanes D, Kraft P. Characterizing associations and SNP-environment interactions for GWAS-identified prostate cancer risk markers-results from BPC3. PLoS ONE 2011;6(2):e17142.
19. Pencina MJ, D'Agostino RB Sr, D'Agostino RB Jr, Vasan RS. Evaluating the added predictive ability of a new marker: From area under the ROC curve to reclassification and beyond. Stat Med 2008;27(2):157-172.
20. Pencina MJ, D'Agostino RB Sr, Steyerberg EW. Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers. Stat Med 2011;30(1):11-21.
21. Steyerberg EW, Harrell FE Jr, Borsboom GJ, Eijkemans MJ, Vergouwe Y, Habbema JD. Internal validation of predictive models: Efficiency of some procedures for logistic regression analysis. J Clin Epidemiol 2001;54(8):774-781.
22. Ferro M, Bruzzese D, Perdona S, Mazzarella C, Marino A, Sorrentino A, Di Carlo A, Autorino R, Di Lorenzo G, Buonerba C, Altieri V, Mariano A, Macchia V, Terracciano D. Predicting prostate biopsy outcome: Prostate health index (phi) and prostate cancer antigen 3 (PCA3) are useful biomarkers. Clinica Chimica Acta 2012;413(15-16):1274-1278.
23. Guazzoni G, Nava L, Lazzeri M, Scattoni V, Lughezzani G, Maccagnano C, Dorigatti F, Ceriotti F, Pontillo M, Bini V, Freschi M, Montorsi F, Rigatti P. Prostate-specific antigen (PSA) isoform p2PSA significantly improves the prediction of prostate cancer at initial extended prostate biopsies in patients with total PSA between 2.0 and 10ng/ml: Results of a prospective study in a clinical setting. Eur Urol 2011;60(2):214-222.
24. Auprich M, Bjartell A, Chun FK, De La Taille A, Freedland SJ, Haese A, Schalken J, Stenzl A, Tombal B, Van Der Poel H. Contemporary role of prostate cancer antigen 3 in the management of prostate cancer. Eur Urol 2011;60(5):1045-1054.
25. Wright JB, Brown SJ, Cole MD. Upregulation of c-MYC in cis through a large chromatin loop linked to a cancer risk-associated single-nucleotide polymorphism in colorectal cancer cells. Mol Cell Biol 2010;30(6):1411-1420.
26. Aly M, Wiklund F, Xu J, Isaacs WB, Eklund M, D'Amato M, Adolfsson J, Grönberg H. Polygenic risk score improves prostate cancer risk prediction: Results from the Stockholm-1 Cohort Study. Eur Urol 2011;60(1):21-28.
27. Zheng SL, Sun J, Wiklund F, Gao Z, Stattin PR, Purcell LD, Adami H-O, Hsu F-C, Zhu Y, Adolfsson J, Johansson J-E, Turner AR, Adams TS, Liu W, Duggan D, Carpten JD, Chang B-L, Isaacs WB, Xu J, Grönberg H. Genetic variants and family history predict prostate cancer similar to prostate-specific antigen. Clin Cancer Res 2009;15(3):1105-1111.
28. Kader AK, Sun J, Reck BH, Newcombe PJ, Kim ST, Hsu FC, D'Agostino RB Jr, Tao S, Zhang Z, Turner AR, Platek GT, Spraggs CF, Whittaker JC, Lane BR, Isaacs WB, Meyers DA, Bleecker ER, Torti FM, Trent JM, McConnell JD, Zheng SL, Condreay LD, Rittmaster RS. Xu J. Potential Impact of adding genetic markers to clinical parameters in predicting prostate biopsy outcomes in men following an initial negative biopsy: Findings from the REDUCE trial. Eur Urol 2012;62(6):953-961.
29. Klein RJ, Hallden C, Gupta A, Savage CJ, Dahlin A, Bjartell A, Manjer J, Scardino PT, Ulmert D, Wallstrom P, Vickers AJ, Lilja H. Evaluation of multiple risk-associated single nucleotide polymorphisms versus prostate-specific antigen at baseline to predict prostate cancer in unscreened men. Eur Urol 2012;61(3):471-477.